Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJHA6Q)

• Drug Name: AR9281 Drug Info
• Synonyms: 1-(Adamantane-1-yl)-3-(1-acetylpiperidine-4-yl)urea; UNII-4HA03Q8EZ9; 4HA03Q8EZ9; CHEMBL436774; 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea; 913548-29-5; Ar9281; AR-9281; Apau (enzyme inhibitor); SCHEMBL654229; 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea; SCHEMBL18464997; MolPort-023-222-910; HUDQLWBKJOMXSZ-UHFFFAOYSA-N; BDBM100423; BDBM50191854; ZINC36330562; AKOS030231617; J3137087F; US8501783, 1153; 1-(adamant-1-yl)-3-(1-acetylpiperidin-4-yl) urea; N-(1-Acetylpiperidin-4-yl)-N'-(adamant-1-yl) urea; N-(1-acetylpiperidin-4-yl)-N'-(adamant-1-yl)urea

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 12000797
  CAS Number: CAS 913548-29-5
  TTD Drug ID: DMJHA6Q
  VARIDT Drug ID: DR00784

Molecule-Related Drug Atlas

Drug(s) Targeting Soluble epoxide hydrolase (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK2256294	DM7FN12	Chronic obstructive pulmonary disease	CA22	Phase 1	[3]
13-n-Heptanamidotridec-8(Z)-enoic acid	DM0LGWJ	Discovery agent	N.A.	Investigative	[4]
N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine	DM2CBNG	Discovery agent	N.A.	Investigative	[5]
1-adamantan-1-yl-3-(6-propyloxyhexyl)urea	DMO1L3I	Discovery agent	N.A.	Investigative	[6]
N-adamantyl-N'-cyclohexylurea	DMZ43N1	Discovery agent	N.A.	Investigative	[2]
13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid	DM689TH	Discovery agent	N.A.	Investigative	[4]
N-(3,3-Diphenyl-propyl)-isonicotinamide	DMOXR4K	Discovery agent	N.A.	Investigative	[7]
1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea	DM8SEJP	Discovery agent	N.A.	Investigative	[8]
1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea	DMAZYCD	Discovery agent	N.A.	Investigative	[9]
1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea	DMYIK9W	Discovery agent	N.A.	Investigative	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble epoxide hydrolase (EPHX2)	TT7WVHI	HYES_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT00847899) Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance. U.S. National Institutes of Health.
• [2] Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
• [3] In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
• [4] 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
• [5] A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
• [6] 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
• [7] Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
• [8] Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
• [9] 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
• [10] Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63.